Detalhe da pesquisa
1.
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Cephalalgia
; 43(5): 3331024231170807, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125484
2.
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
Eur J Neurol
; 30(4): 1089-1098, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36583633
3.
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
J Headache Pain
; 23(1): 153, 2022 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460983
4.
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet Neurol
; 21(7): 597-607, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35716692
5.
Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial.
J Alzheimers Dis
; 29(2): 459-69, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22269160
6.
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Int J Geriatr Psychiatry
; 22(3): 258-62, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17243195